Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local privacy regulations.
Definite diagnosis of relapsing-onset MS according to the revised McDonald 2017 criteria
Treatment with one of the first-line DMTs: any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide
Complete absence of inflammatory activity (no objectively defined and confirmed relapses, no significant number (2 or more) of new-T2 lesions and no contrast-enhancing lesions) for 5 consecutive years under first-line treatment
You may not be if
A switch between first-line disease modifying therapy over two years prior to inclusion, in case the switch has been due to in effectivity of the first DMT.
Women who want to discontinue medication because of a pregnancy wish and women who are pregnant or expect to become pregnant during the study period
Patients that have previously used interferon-beta and have been tested positive for neutralizing antibodies (NAbs).
